Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti tumour activity.

In English

Författare

Summary, in English

The Tn antigen (GalNAc alpha-O-Ser/Thr) is heterogeneously synthesised by a variety of tumours and contains an epitope defined by lectins and antibodies as a cluster of alpha GalNAc carbohydrates synthesised within a peptide sequence, which is rich in serine and/or threonine. The Tn antigen has been utilized as a target in vaccine experiments and also used as a biomarker for prognosis of different cancer forms. In this paper we present a new monoclonal antibody, GOD3-2C4, with the clear hallmarks of an anti-Tn antibody. It was generated through somatic cell hybridisation after immunisation of a mouse with a tumour cell line and a Tn carrying mucin. The antibody recognises synthetic Tn antigen and binds breast, colon, lung, ovarian and pancreas cancer. The GOD3-2C4 antibody has ADCC activity against Jurkat cells in vitro and for the first time it can be shown that an anti-Tn antibody has a significant in vivo effect on a human cancer cell line grown as a xenograft in SCID mice.

Avdelning/ar

  • Bröstcancer-genetik
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publiceringsår

2011

Språk

Engelska

Sidor

1097-1107

Publikation/Tidskrift/Serie

Glycobiology

Volym

21

Issue

8

Dokumenttyp

Artikel i tidskrift

Förlag

Oxford University Press

Ämne

  • Biochemistry and Molecular Biology

Nyckelord

  • monoclonal antibody
  • in vivo therapy
  • antigen
  • Tn
  • anti-carbohydrate
  • biomarker

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1460-2423